Report
Hyloris Pharma - All eyes on October 17
Last night, Hyloris provided its H1 update revealing a rather modest increase in Maxigesic® IV and Sotalol IV sales revenue vs. H1 2022. US launch of Maxigesic® IV and higher royalty % on Sotalol IV sales expected to ramp up product revenue going forward.No new asset announcements but the company 1/ reiterates its ‘30 assets by 2025' strategy and 2/ believes it is sufficiently capitalized to fund R&D expenses of its current 17 product candidates.We have trimmed our TP to EUR 19 (vs EUR 19.5) after 1/ incorporating the expected EUR 2m milestone payment associated with the US approval and
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.